Generally speaking, we have come far for CMV. And the session was, I presented the adult guidelines. My colleague Jan Styczynski from Poland presented the situation in children. And a colleague from the United States, Genovefa Papanikolaou, talked about where we are going and what can we expect for the future. And I think we are making steps all the time in better controlling CMV in our patients...
Generally speaking, we have come far for CMV. And the session was, I presented the adult guidelines. My colleague Jan Styczynski from Poland presented the situation in children. And a colleague from the United States, Genovefa Papanikolaou, talked about where we are going and what can we expect for the future. And I think we are making steps all the time in better controlling CMV in our patients. But of course, as I had on one of my slides, a foe worthy of attack proves its worth by hitting back. And CMV is still important for us, although it’s not as bad as it was when I started doing transplants by now almost 45 years ago.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
